Novartis’ RemIND trial of oral remibrutinib meets...
Category : Clinical Trial Update 20 February 2026The trial is assessing remibrutinib's safety, tolerability and efficacy in adults with CIndU unr...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
Samsung Health announces ‘Find Care’ feature in pa...
Category : Licensing/Collaboration Deal 20 February 2026Samsung, India’s leading consumer electronics brand, has announced a partnership between Samsu...
Zydus introduces biosimilar Aflibercept 2 mg Anyra...
Category : Approval/Launch 20 February 2026Zydus Lifesciences Ltd., an innovation-led global life sciences company, announced the launch of Any...
SMSR & Sharda University set up Centre for Drug Qu...
Category : Licensing/Collaboration Deal 20 February 2026School of Medical Sciences & Research (SMSR) in collaboration with the School of Pharmacy, Shard...
Asahi Kasei Pharma and Alchemedicine Advance a Nov...
Category : Clinical Trial Update 19 February 2026Asahi Kasei Pharma, a global provider of healthcare and pharmaceutical solutions, in collaboration w...
Latest Newsletter Post
-
SMSR & Sharda University set up Cen..
20 February 2026
-
Zydus introduces biosimilar Afliber..
20 February 2026
-
Samsung Health announces ‘Find Care..
20 February 2026
-
Novartis’ RemIND trial of oral remi..
20 February 2026
-
The New England Journal of Medicine..
19 February 2026
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com